logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5829.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5829.produseast1
Showing 1 - 5 of 5 Items
Showing 1 - 5 of 5 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (5)
  • CSV
  • BibTeX
  • EndNote
  • All Results (5)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Characterizing treatment adherence trajectories in the endTB multisite cohort of drug-resistant tuberculosis patients: an application of group-based trajectory modelling

Law S, Fulcher I, Ashraf S, Bastard M, Docteur W,  et al.
2025-08-22 • Clinical Infectious Diseases
2025-08-22 • Clinical Infectious Diseases

BACKGROUND

In tuberculosis (TB) care, adherence is often assessed using a simple 80% threshold, ...

Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country multidrug-resistant/rifampicin-resistant tuberculosis cohort

Khan U, Rich M, Franke MF, Lachenal N, Ahmed S,  et al.
2025-08-01 • Clinical Infectious Diseases
2025-08-01 • Clinical Infectious Diseases

BACKGROUND

The 2022 World Health Organization (WHO) guidelines on multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) recommend 6 months of bedaqu...

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country MDR/RR-TB cohort

Khan U, Rich M, Franke M, Lachenal N, Ahmed S,  et al.
2024-12-10 • Clinical Infectious Diseases
2024-12-10 • Clinical Infectious Diseases

BACKGROUND

The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen ...

Culture conversion in patients treated with bedaquiline and/or delamanid. A prospective multicountry study

Franke MF, Khan P, Hewison C, Khan U, Huerga H,  et al.
2021-01-01 • American Journal of Respiratory and Critical Care Medicine
2021-01-01 • American Journal of Respiratory and Critical Care Medicine
RATIONALE
Bedaquiline and delamanid offer the possibility of more effective and less toxic treatment for multidrug-resistant (MDR) tuberculosis (TB). With this treatment, however, so...

Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion

Rodriguez CA, Lodi S, Horsburgh CR, Bastard M, Hewison C,  et al.
2022-11-10 • PLOS One
2022-11-10 • PLOS One

BACKGROUND

Con...